Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment

被引:70
|
作者
Zardi, E. M. [1 ]
Navarini, L. [1 ]
Sambataro, G. [1 ]
Piccinni, P. [1 ]
Sambataro, F. M. [1 ]
Spina, C. [1 ]
Dobrina, A. [2 ]
机构
[1] Univ Campus Biomed, Dept Clin Med, I-00128 Rome, Italy
[2] Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy
关键词
Cytokines; genes; HSCs; ligands; liver fibrosis; microcirculation; PPARs; antifbrotic therapy; transcription factors; PROLIFERATOR-ACTIVATED-RECEPTOR; HEPATOCYTE GROWTH-FACTOR; STELLATE CELL ACTIVATION; ALCOHOLIC FATTY LIVER; NF-KAPPA-B; SINUSOIDAL ENDOTHELIAL-CELLS; ATTENUATING OXIDATIVE STRESS; ISCHEMIA-REPERFUSION INJURY; PEROXISOMAL BETA-OXIDATION; EXTRACELLULAR-MATRIX GENES;
D O I
10.2174/09298673113209990136
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Complex molecular and cellular mechanisms are involved in the pathway of liver fibrosis. Activation and transformation of hepatic stellate cells (HSCs) are considered the two main reasons for the cause and development of liver fibrosis. The peroxisome proliferator-activated receptors (PPARs) belonging to the family of ligand-activated transcription factors play a key role in liver homeostasis, regulating adipogenesis and inhibiting fibrogenesis in HSCs. Normal transcriptional function of PPARs contributes to maintain HSCs in quiescent phase. A reduced expression of PPARs in HSCs greatly induces a progression of liver fibrosis and an increased production of collagen. Here, we discuss role and function of PPARs and we take into consideration molecular factors able to reduce PPARs activity in HSCs. Finally, although further validations are needed, we illustrate novel strategies available from in vitro and animal studies on how some PPARs-agonists have been proved effective as antifibrotic substances in liver disease.
引用
收藏
页码:3370 / 3396
页数:27
相关论文
共 50 条
  • [1] PPARs in liver physiology
    Berthier, Alexandre
    Johanns, Manuel
    Zummo, Francesco Paolo
    Lefebvre, Philippe
    Staels, Bart
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2021, 1867 (05):
  • [2] The Role of PPARs in Lung Fibrosis
    Lakatos, Heather F.
    Thatcher, Thomas H.
    Kottmann, R. Matthew
    Garcia, Tatiana M.
    Phipps, Richard P.
    Sime, Patricia J.
    PPAR RESEARCH, 2007, 2007
  • [3] Liver myofibroblasts:: Physiology, role in liver fibrosis and liver cancer, and pharmacological modulation
    de Lédinghen, V
    Godichaud, S
    Krisa, S
    Faouzi, S
    Monvoisin, A
    Neaud, V
    Rosenbaum, J
    PHARMACEUTICAL BIOLOGY, 1998, 36 : 69 - 74
  • [4] Role of MMPs and TIMPs on hepatic fibrosis - Their althelations in progress of liver fibrosis
    Nishizaki, Y
    Watanabe, N
    Nakano, A
    Kagawa, T
    Okazaki, Y
    Wasada, M
    Nagata, N
    Kawazoe, K
    Hosoi, K
    Takashimizu, S
    Matsuzaki, S
    GASTROENTEROLOGY, 1996, 110 (04) : A1279 - A1279
  • [5] ROLE OF HEPATIC SINUSOIDAL CELLS IN HEPATIC-INJURY AND FIBROSIS IN THE LIVER
    SHIRATORI, Y
    KAWASE, T
    SHIINA, S
    KOMATSU, Y
    OMATA, M
    GASTROENTEROLOGIA JAPONICA, 1993, 28 : 102 - 106
  • [6] Hepatic stellate cells: a target for the treatment of liver fibrosis
    Jian Wu
    Mark A. Zern
    Journal of Gastroenterology, 2000, 35 : 665 - 672
  • [7] Hepatic stellate cells: a target for the treatment of liver fibrosis
    Wu, J
    Zern, MA
    JOURNAL OF GASTROENTEROLOGY, 2000, 35 (09) : 665 - 672
  • [8] Hepatic stellate cells as a target for the treatment of liver fibrosis
    Bataller, R
    Brenner, DA
    SEMINARS IN LIVER DISEASE, 2001, 21 (03) : 437 - 451
  • [9] Dystroglycan expression in hepatic stellate cells:: Role in liver fibrosis
    Bedossa, P
    Ferlicot, S
    Paradis, V
    Dargère, D
    Bonvoust, F
    Vidaud, M
    LABORATORY INVESTIGATION, 2002, 82 (08) : 1053 - 1061
  • [10] Hyperhomocysteinemia in liver cirrhosis mechanisms and role in vascular and hepatic fibrosis
    García-Tevijano, ER
    Berasain, C
    Rodríguez, JA
    Corrales, FJ
    Arias, R
    Martín-Duce, A
    Caballería, J
    Mato, JM
    Avila, MA
    HYPERTENSION, 2001, 38 (05) : 1217 - 1221